Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis

被引:0
作者
Stefan Wöhrer
Barbara Kiesewetter
Julia Fischbach
Leonhard Müllauer
Marlene Troch
Julius Lukas
Marius E. Mayerhoefer
Markus Raderer
机构
[1] Medical University of Vienna,Division of Bone Marrow Transplantation, Department of Internal Medicine 1
[2] Medical University of Vienna,Division of Oncology, Department of Internal Medicine 1
[3] Medical University of Vienna,Department of Pathology
[4] Medical University of Vienna,Department of Internal Medicine I
[5] Medical University of Vienna,Department of Ophthalmology
[6] Medical University Vienna,Department of Radiology
来源
Annals of Hematology | 2014年 / 93卷
关键词
MALT lymphoma; Antibacterial agents; Drug therapy; Surgery; Radiotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
We have performed a retrospective analysis of all patients with extragastric mucosa-associated lymphoid tissue (MALT) lymphoma treated at our institution to compare the efficacy of first-line therapeutic modalities including surgery, radiation, systemic therapy, and antibiotics. One hundred eighty-five patients with extragastric MALT lymphoma with a median age of 63 (interquartile range (IQR) 50–74) years and a median follow-up time of 49 (IQR 18–103) months were retrospectively analyzed. Time to progression and time to next therapy were used as surrogate endpoints for efficacy. Patients having either surgery (100 %), chemo/immunotherapy (85.5 %), or radiation (80 %) had significantly (p = 0.01) higher response rates than patients treated with antibiotics (33.3 %). Patients who were irradiated had significantly more progressive disease, but also the longest follow-up time. Stage, elevated LDH, anemia, elevated beta-2 microglobulin, plasmacytic differentiation, monoclonal gammopathy, or autoimmune disease did not influence the rate of disease progression nor did complete remission or partial remission from initial therapy influence time to and rate of progression. There was no significant difference in the median time to progression (p = 0.141), but the estimated time to progression (p = 0.023) as well as the estimated time to next therapy (p = 0.021) was significantly different among the various cohorts favoring surgery, chemo/immunotherapy, and radiation. Our results suggest extragastric MALT lymphoma as a potential systemic disease irrespective of initial stage. Radiation, surgery, and chemo/immunotherapy seem to be equally effective in achieving remissions and prolonged progression free survivals, but a curative potential is questionable. Localized MALT lymphomas affecting the thyroid gland or the lungs have excellent long-term progression-free survivals with surgical treatment only.
引用
收藏
页码:1287 / 1295
页数:8
相关论文
共 95 条
  • [1] Harris NL(2000)The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 Mod Pathol 13 193-207
  • [2] Jaffe ES(2011)Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells Br J Haematol 155 362-365
  • [3] Diebold J(1993)The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Lancet 342 571-574
  • [4] Novak U(2003)Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue Blood 101 2489-2495
  • [5] Basso K(2004)Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection Br J Haematol 126 43-49
  • [6] Pasqualucci L(2007)Characterization of B cell lymphoma in patients with Sjogren’s syndrome and hepatitis C virus infection Arthritis Rheum 57 161-170
  • [7] Hussell T(2008)Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas J Hepatol 49 170-174
  • [8] Isaacson PG(1993)Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Lancet 342 575-577
  • [9] Crabtree JE(1997)Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma Leuk Lymphoma 26 527-537
  • [10] Zucca E(2011)EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT Gut 60 747-758